Cite
HARVARD Citation
Platten, M. et al. (n.d.). OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas. Neuro-oncology. pp. iii226-iii227. [Online].